| Title: |
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma |
| Authors: |
Sonneveld P.; Dimopoulos M. A.; Boccadoro M.; Quach H.; Ho P. J.; Beksac M.; Hulin C.; Antonioli E.; Leleu X.; Mangiacavalli S.; Perrot A.; Cavo M.; Belotti A.; Broijl A.; Gay F.; Mina R.; Nijhof I. S.; Van De Donk N. W. C. J.; Katodritou E.; Schjesvold F.; Sureda Balari A.; Rosiñol L.; Delforge M.; Roeloffzen W.; Silzle T.; Vangsted A.; Einsele H.; Spencer A.; Hajek R.; Jurczyszyn A.; Lonergan S.; Ahmadi T.; Liu Y.; Wang J.; Vieyra D.; Van Brummelen E. M. J.; Vanquickelberghe V.; Sitthi-Amorn A.; De Boer C. J.; Carson R.; Rodriguez-Otero P.; Bladé J.; Moreau P. |
| Contributors: |
Sonneveld P.; Dimopoulos M.A.; Boccadoro M.; Quach H.; Ho P.J.; Beksac M.; Hulin C.; Antonioli E.; Leleu X.; Mangiacavalli S.; Perrot A.; Cavo M.; Belotti A.; Broijl A.; Gay F.; Mina R.; Nijhof I.S.; Van De Donk N.W.C.J.; Katodritou E.; Schjesvold F.; Sureda Balari A.; Rosiñol L.; Delforge M.; Roeloffzen W.; Silzle T.; Vangsted A.; Einsele H.; Spencer A.; Hajek R.; Jurczyszyn A.; Lonergan S.; Ahmadi T.; Liu Y.; Wang J.; Vieyra D.; Van Brummelen E.M.J.; Vanquickelberghe V.; Sitthi-Amorn A.; De Boer C.J.; Carson R.; Rodriguez-Otero P.; Bladé J.; Moreau P. |
| Publication Year: |
2024 |
| Collection: |
IRIS Università degli Studi di Bologna (CRIS - Current Research Information System) |
| Subject Terms: |
Daratumumab; Bortezomib; Lenalidomide; Dexamethasone; Multiple Myeloma |
| Description: |
BackgroundDaratumumab, a monoclonal antibody targeting CD38, has been approved for use with standard myeloma regimens. An evaluation of subcutaneous daratumumab combined with bortezomib, lenalidomide, and dexamethasone (VRd) for the treatment of transplantation-eligible patients with newly diagnosed multiple myeloma is needed.MethodsIn this phase 3 trial, we randomly assigned 709 transplantation-eligible patients with newly diagnosed multiple myeloma to receive either subcutaneous daratumumab combined with VRd induction and consolidation therapy and with lenalidomide maintenance therapy (D-VRd group) or VRd induction and consolidation therapy and lenalidomide maintenance therapy alone (VRd group). The primary end point was progression-free survival. Key secondary end points were a complete response or better and minimal residual disease (MRD)-negative status.ResultsAt a median follow-up of 47.5 months, the risk of disease progression or death in the D-VRd group was lower than the risk in the VRd group. The estimated percentage of patients with progression-free survival at 48 months was 84.3% in the D-VRd group and 67.7% in the VRd group (hazard ratio for disease progression or death, 0.42; 95% confidence interval, 0.30 to 0.59; P |
| Document Type: |
article in journal/newspaper |
| File Description: |
ELETTRONICO |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/38084760; info:eu-repo/semantics/altIdentifier/wos/WOS:001123969000001; volume:390; issue:4; firstpage:301; lastpage:313; numberofpages:13; journal:THE NEW ENGLAND JOURNAL OF MEDICINE; https://hdl.handle.net/11585/969802 |
| DOI: |
10.1056/NEJMoa2312054 |
| Availability: |
https://hdl.handle.net/11585/969802; https://doi.org/10.1056/NEJMoa2312054; https://www-nejm-org.ezproxy.unibo.it/doi/10.1056/NEJMoa2312054 |
| Rights: |
info:eu-repo/semantics/openAccess |
| Accession Number: |
edsbas.885D77DA |
| Database: |
BASE |